中文

CELERZOA / A complete barrier resilience solution

Rebuild the barrier at every level.

Created for rapid comfort and structured barrier recovery in demanding professional-care scenarios.

Contact our team
A complete barrier resilience solution
A complete barrier resilience solution

Created for rapid comfort and structured barrier recovery in demanding professional-care scenarios.

A complete barrier resilience solution

Professional Edition

-18°C cryogenic active essence

1 mL single-dose concentrated essence

A high-concentration protocol proposed for professional use after procedures such as laser, microneedling and intensive hydration care.

Proposed -18°C cold-chain storage

Home Edition

28-day barrier rebuilding set

21 mg freeze-dried sphere + 1 mL activating solution

A seven-day staged course that moves from immediate comfort to longer-term barrier support.

Proposed 2 to 8°C refrigerated storage

Product action concept

Every step has a clear task.

Calm

Help reduce the look of visible redness and ease stressed-skin discomfort.

Rebuild

Support a more complete and resilient-looking protective barrier.

Repair

Improve the appearance of roughness, post-blemish marks and dull tone.

Formula and intended use.

Formula architecture

  • CELERZOA proprietary ingredient concept
  • Multi-active protein, peptide and amine complex
  • High-purity active nucleic acid essence
  • Multi-dimensional botanical complex

Designed for

  • Compromised or sensitivity-prone skin barriers
  • Stress redness and recurring congestion
  • Post-blemish marks and dull-looking skin
  • Skin needing structured post-procedure care

One standard from research to care.

Three principles hold the experience together from laboratory to protocol.

Clinical focus

Protocols developed for professional-grade care scenarios.

Deep research roots

Built on decades of biomedical exploration and cell-signalling research.

Core technology

A delivery and preservation system designed around active ingredients.

* Technical, efficacy and compliance statements are pending final review.